Navigation Links
Dermata Therapeutics, LLC Closes a $5 Million Series 1a Financing and Secures a $5 Million Credit Facility with Silicon Valley Bank
Date:2/16/2017

SAN DIEGO, Feb. 16, 2017 /PRNewswire/ -- Dermata Therapeutics, LLC, a biotechnology company developing new and innovative products to treat a variety of dermatological diseases, today announced it has completed a $5 million Series 1a financing and entered into a $5 million credit facility with Silicon Valley Bank (SVB).  Dermata intends to use the capital for general corporate purposes to further Dermata's mission of making major advancements in the treatment of serious diseases treated by dermatologists.  

"We believe this funding strategy will provide us with the necessary capital to complete our two ongoing Phase 2 clinical studies with our lead candidate DMT210 in atopic dermatitis and rosacea. Moreover, it aligns us with a premier partner in SVB, helping us manage our cost of capital moving forward and providing the opportunity for significant value creation for our unit holders," states Gerald Proehl, President and CEO of Dermata. 

Dermata received $2.5 million at closing and, under the terms of the agreement, will receive an additional $2.5 million later this year, subject to achievement of certain specified milestones.

About Dermata: Dermata is a development-stage biotechnology company focused on making major advancements in the treatment of serious diseases treated by dermatologists. Dermata has an experienced team who are currently focused on progressing four programs for the treatment of acne rosacea, atopic dermatitis, acne vulgaris and ocular rosacea.  To learn more about Dermata and its pipeline of treatments, please visit www.dermatarx.com.


CONTACT:

Dermata ContactSean ProehlInvestor Relations858.223.0882sproehl@dermatarx.com


 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dermata-therapeutics-llc-closes-a-5-million-series-1a-financing-and-secures-a-5-million-credit-facility-with-silicon-valley-bank-300408534.html


'/>"/>
SOURCE Dermata Therapeutics, LLC
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Dermata Therapeutics, LLC Announces Initiation of Treatment in a Phase 2 Atopic Dermatitis Study
2. Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific
3. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
4. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
5. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
6. Global Aptamers Market Technology Trend Analysis Market Report 2013-2018: Therapeutics, Diagnostics, Biosensors, Biomarker/Drug Discovery & Applications
7. Orexigen Therapeutics, Inc. Prices Offering of $100 Million of Convertible Senior Notes
8. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
9. Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
10. Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma
11. Immunomic Therapeutics, Inc. Makes Significant Headway in Regulatory Interactions in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
Breaking Biology Technology:
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... 2017 No two people are believed ... New York University Tandon School of Engineering and ... that partial similarities between prints are common enough ... phones and other electronic devices can be more ... lies in the fact that fingerprint-based authentication systems ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
Breaking Biology News(10 mins):